Stem cell subpopulations with differential gstt1 expression or genotype
AssigneeAgency for Science, Technology and Research
InventorsLawrence Stanton, Padmapriya Sathiyanathan, Simon Cool, Victor Nurcombe, Rebekah M. Samsonraj
Life of this patent
Estimating the term…
Abstract
A method for providing a sub-population of stem cell or plurality of stem cells by determining or modulating GSTT1 expression level or genotype is disclosed together with uses of the stem cells.
Claims19
A method for identifying a stem cell or plurality of stem cells, the method comprising determining the level of GSTT1 expression in said stem cell or plurality of stem cells.
A method for identifying a stem cell or plurality of stem cells, the method comprising determining the GSTT1 genotype of the stem cell or plurality of stem cells.
-18. (canceled)
A method for selecting a stem cell donor, the method comprising:
- (a) determining the genotype for GSTT1 in a DNA-containing sample isolated from an individual, wherein an individual determined to have a GSTT1 genotype which is known, and/or which would be predicted, to result in decreased expression of GSTT1 relative to individuals homozygous for wildtype GSTT1 is selected as a stem cell donor;
- or
- (b) determining the level of GSTT1 expression by a stem cell or plurality of stem cells in a sample isolated from an individual, and comparing the determined level of GSTT1 expression to a reference value for the level of GSTT1 expression for that stem cell type, wherein an individual determined to have a stem cell or plurality of stem cells having decreased GSTT1 expression relative to the reference value is selected as a stem cell donor.
(canceled)
-25. (canceled)
A method of treatment comprising, administering to an individual in need of treatment a therapeutically effective amount of a stem cell or plurality of stem cells wherein the stem cells are selected by
- (a) determining the genotype for GSTT1 in a DNA-containing sample isolated from an individual, wherein an individual determined to have a GSTT1 genotype which is known, and/or which would be predicted, to result in decreased expression of GSTT1 relative to individuals homozygous for wildtype GSTT1 is selected as a stem cell donor;
- (b) obtaining a mesenchymal stem cell (MSC) or plurality of MSCs by isolating a MSC or plurality of MSCs from the individual selected as a stem cell donor, wherein the MSCs exhibit one or more of the following properties
- (i) enhanced colony forming capacity;
- (ii) reduced cell size;
- (iii) increased telomere length and/or a reduced rate of telomere shortening;
- (iv) increased expression of STRO-1, SSEA-4, CD146 and/or PDGFRβ;
- (v) increased secretion of FGF-2, VEGF, SDF-1α, fractalkine, PDGF-BB and/or MIP-1α;
- (vi) enhanced suppression of T cells;
- (vii) decreased expression of ALP, RUNX2 and/or BSP-II;
- (viii) increased expression of TWIST-1 and DERMO-1;
- and
- (c) administering the obtained stem cell or plurality of stem cells to the individual in need of treatment.
Dependencies are inferred from the claim text.